IGF2 and cancer: FZD8, plasminogen activator, urokinase receptor, ITGA2, WNT2B, TIMP3, WNT5B, FGF5, heparanase, HBEGF and WNT3A were up-regulated in the proteoglycan pathways in cancer, whereas WNT10A, PIK3R3, IGF2 were down-regulated.